It is known that Sphingosine-1-phosphate mediates migration of mesenchymal stem cells. However, there are numerous receptors by which the effects of sphingosine-1-phosphate are mediated. While the sphingosine-1-phosphate receptor 1 is associated with migration, other activation of other receptors (such as sphingosine-1-phosphate receptors 2-5) is associated with adverse events such as hypotension or bradycardia.
The current patent covers some novel compositions of matter that selectively modulate activity of sphingosine-1-phosphate receptor 1. The use of these compounds for treatment of autoimmunity, modulation of stem cell migration, and treatment of transplant rejection is also covered.